Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

CXCL8 (Chemokine (C-X-C motif) ligand 8)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related tests:

‹

MelaNodal Predict™

MelaNodal Predict™

›

CXCL8 elevation	Hepatocellular Cancer	CXCL8 elevation	Hepatocellular Cancer	cabozantinib tablet Resistant: B - Late Trials cabozantinib tablet Resistant : B	cabozantinib tablet Resistant: B - Late Trials cabozantinib tablet Resistant : B
CXCL8 elevation	Gastric Cancer	CXCL8 elevation	Gastric Cancer	nivolumab + ramucirumab Sensitive: C3 – Early Trials nivolumab + ramucirumab Sensitive : C3	nivolumab + ramucirumab Sensitive: C3 – Early Trials nivolumab + ramucirumab Sensitive : C3
CXCL8-L	Renal Cell Carcinoma	CXCL8-L	Renal Cell Carcinoma	pazopanib Sensitive: C3 – Early Trials pazopanib Sensitive : C3	pazopanib Sensitive: C3 – Early Trials pazopanib Sensitive : C3
CXCL8 elevation	Urothelial Cancer	CXCL8 elevation	Urothelial Cancer	atezolizumab Resistant: C3 – Early Trials atezolizumab Resistant : C3	atezolizumab Resistant: C3 – Early Trials atezolizumab Resistant : C3
CXCL8 elevation	Renal Cell Carcinoma	CXCL8 elevation	Renal Cell Carcinoma	atezolizumab Resistant: C3 – Early Trials atezolizumab Resistant : C3	atezolizumab Resistant: C3 – Early Trials atezolizumab Resistant : C3
CXCL8 elevation	Cervical Cancer	CXCL8 elevation	Cervical Cancer	ipilimumab Resistant: C3 – Early Trials ipilimumab Resistant : C3	ipilimumab Resistant: C3 – Early Trials ipilimumab Resistant : C3
CXCL8-L	Ovarian Cancer	CXCL8-L	Ovarian Cancer	bevacizumab + sorafenib Sensitive: C3 – Early Trials bevacizumab + sorafenib Sensitive : C3	bevacizumab + sorafenib Sensitive: C3 – Early Trials bevacizumab + sorafenib Sensitive : C3
CXCL8 elevation	Non Small Cell Lung Cancer	CXCL8 elevation	Non Small Cell Lung Cancer	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3
CXCL8 elevation	Head and Neck Cancer	CXCL8 elevation	Head and Neck Cancer	cetuximab Resistant: C3 – Early Trials cetuximab Resistant : C3	cetuximab Resistant: C3 – Early Trials cetuximab Resistant : C3
CXCL8 expression	Squamous Cell Carcinoma of Head and Neck	CXCL8 expression	Squamous Cell Carcinoma of Head and Neck	pembrolizumab Resistant: C3 – Early Trials pembrolizumab Resistant : C3	pembrolizumab Resistant: C3 – Early Trials pembrolizumab Resistant : C3
CXCL8 elevation	Clear Cell Renal Cell Carcinoma	CXCL8 elevation	Clear Cell Renal Cell Carcinoma	nivolumab Resistant: C3 – Early Trials nivolumab Resistant : C3	nivolumab Resistant: C3 – Early Trials nivolumab Resistant : C3
CXCL8 elevation	Diffuse Large B Cell Lymphoma	CXCL8 elevation	Diffuse Large B Cell Lymphoma	axicabtagene ciloleucel Resistant: C3 – Early Trials axicabtagene ciloleucel Resistant : C3	axicabtagene ciloleucel Resistant: C3 – Early Trials axicabtagene ciloleucel Resistant : C3